Skip to main content
Figure 2 | Lipids in Health and Disease

Figure 2

From: Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe

Figure 2

Changes in lipid profiles between baseline and 4, 8 and 12 weeks after randomization. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; T-Cho, total cholesterol; TG, triglycerides. *p < 0.05 versus rosuvastatin 2.5 mg/day + ezetimibe 10 mg/day.

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X